IL28B Proteins, Antibodies, cDNA Clones Research Reagents

IFNL3 (Interferon Lambda 3, also known as IL28B; IL28C; IL-28B; IL-28C; IFN-lambda-3; IFN-lambda-4), located on 19q13.2, is a Protein Coding gene. The gene produces a 21706 Da protein composed of 196 amino acids. IL28B is a class II cytokine receptor (e.g., IFNAR1) ligand related to type I interferons. It has a conserved cysteine pattern and amphipathic profile similar to other helical cytokine family members. IL28B functions in Up-regulating MHC class I antigen expression. Diseases such as Hepatitis C Virus and Htlv-1 Associated Myelopathy/Tropical Spastic Paraparesis are associated with IFNL3.

IL28B Protein (3)

    IL28B Antibody (6)

      IL28B cDNA Clone (16)


      In expression vector

      In lentiviral vector


      In expression vector


      クローニングベクター cDNA 製品

      In lentiviral vector

      IL28B Lysate (2)

        IL28B の背景知識

        Interleukin-28B (IL-28B) also known as Interferon lambda-3 and IFN-lambda-3, belongs to the type III interferon family of cytokines and are highly similar to IL-29. IL-28B belongs to the newly described interferon lambda (IFNλ) family of cytokines. IL-28B is a cytokine with immunomodulatory activity. It functions in Up-regulating MHC class I antigen expression. IL-28B displays potent antiviral activity and antitumor activity. This cytokine serves as a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IL28RA. The ligand/receptor complex seems to signal through the Jak-STAT pathway. IL-28B, like IL-12, is capable of robustly enhancing adaptive immunity. Moreover, we describe for the first time how IL-28B reduces regulatory T-cell populations during DNA vaccination, whereas IL-12 increases this cellular subset. We also show that IL-28B, unlike IL-12, can increase the percentage of splenic CD8+ T cells in vaccinated animals and that these cells are more granular and have higher antigen-specific cytolytic degranulation compared with cells taken from animals that received IL-12 as an adjuvant.

        IL28B の参考文献

        • Ge D, et al.. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 461(7262): 399-401.
        • Morrow MP, et al.. (2009) Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood. 113(23): 5868-77.
        • Sheppard P, et al.. (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 4(1): 63-8.

        Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.